ArticleInternational journal of technology assessment in health care2026
Horizon scan of the clinical development landscape of biosimilar products in the UK and EU.
Article in International journal of technology assessment in health care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesBiosimilars are biological medicines highly similar to an authorized reference medicine, offering substantial cost savings and increased treatment access. Despite the regulatory framework in the UK and EU facilitating their approval, the biosimilar landscape remains small compared to small-molecule drugs. This study provides a horizon scanning overview of the current biosimilar landscape, procured through horizon scanning activities.
methodsData were sourced from ClinicalTrials.gov and the EU Clinical Trials Register, scanned monthly to identify innovative medicines in clinical development. We included biosimilars identified through horizon scanning from April 2017 to February 2025. Supplementary data were collected from the European Medicines Agency to ascertain approval status, and additional clinical trial information was manually extracted from relevant registries.
resultsWe identified 156 unique biosimilars developed across 174 clinical trials, with sixty-four approved by the MHRA and seventy-eight by the European Medicines Agency. Adalimumab, bevacizumab, and denosumab were the reference products with the most biosimilars in development. Most biosimilar trials were at phase III. There are seventy-one biosimilars in active development.
conclusionsThe development landscape of biosimilars in the UK and EU show high activity levels. Continuous improvements in horizon scanning methods and regulatory frameworks are essential to support the timely adoption of biosimilars, maximizing their benefits for healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.